Corbus Pharmaceuticals Announces Preclinical Data

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) announced that Michael Knowles, M.D., a member of the Company’s Scientific Advisory Board and Professor of Pulmonary and Critical Care Medicine, University of North Carolina Chapel Hill will present findings on JBT-101 reducing inflammatory mediators in alveolar macrophages isolated from excised lungs of cystic fibrosis (CF) patients. The presentation is slated for March 13, 2017, in New York City, at the Research and Development Day hosted by Corbus.
As quoted in the press release:

“This human model has allowed us to explore the impact of JBT-101 on immune function of primary cells derived from CF patients’ lungs. The data demonstrate JBT-101’s unique mechanism of action that could help address chronic lung inflammation in CF patients potentially without the immunosuppression risk associated with existing anti-inflammatory therapies that render them inappropriate for usage in this disease,” stated Mark A. Tepper PhD, President and Chief Scientific Officer of Corbus. “We look forward to our upcoming Phase 2 clinical data of JBT-101 in CF patients for further insight into this potential benefit.”

Click here for the full press release.